Immuno-metabolic impact of the multiple sclerosis patients' sera on endothelial cells of the blood-brain barrier

• Published in: Journal of neuroinflammation Vol. 17; no. 1; p. 153
• Main Authors: Sheikh, M H, Henson, S M, Loiola, R A, Mercurio, S, Colamatteo, A, Maniscalco, G T, De Rosa, V, McArthur, S, Solito, E
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 09.05.2020; BioMed Central; BMC
• Subjects: Acidification; Adult; Autoimmune diseases; Blood-brain barrier; Blood-Brain Barrier - metabolism; Body mass index; Cadherins; Capillary Permeability - immunology; Cell adhesion; Cell adhesion molecules; Cell metabolism; Cells, Cultured; Cerebral circulation; Cytoskeleton; Diagnosis; Endothelial cells; Endothelium; Endothelium, Vascular - metabolism; Extravasation; Female; Glucose; Glucose transporter; Glycolysis; Health aspects; Humans; Immunological tolerance; Inflammation; Intercellular adhesion molecule 1; Male; Membrane potential; Metabolism; Microvasculature; Mitochondria; Multiple sclerosis; Multiple Sclerosis, Relapsing-Remitting - blood; Multiple Sclerosis, Relapsing-Remitting - immunology; Oxidative phosphorylation; Oxygen consumption; P-Glycoprotein; Permeability; Reactive oxygen species; Signal transduction; Tight junction; Transendothelial and Transepithelial Migration - immunology; Vascular endothelium; United Kingdom; Cytoskeleton; Tight junction; Multiple sclerosis; Blood-brain barrier; Metabolism
• ISSN: 1742-2094; 1742-2094
• DOI: 10.1186/s12974-020-01810-8

Multiple sclerosis (MS) is an autoimmune disease which results from the invasion of the brain by activated immune cells across the endothelial cells (ECs) of the blood-brain barrier (BBB), due to loss of immune self-tolerance. Many reports define the metabolic profile of immune cells in MS, however little is known about the metabolism of the BBB ECs during the disease. We aim to determine whether circulating factors in MS induce metabolic alterations of the BBB ECs compared to a healthy state, which can be linked with disruption of BBB integrity and subsequent immune cell extravasation. In this report, we used an in vitro model to study the effect of sera from naïve-to-treatment, relapsing-remitting MS (RRMS) patients on the human brain microvascular endothelium, comparing effects to age/sex-matched healthy donor (HD) sera. Our data show that RRMS serum components affect brain endothelial cells by impairing intercellular tightness through the down-modulation of occludin and VE-cadherin, and facilitating immune cell extravasation through upregulation of intercellular adhesion molecules (ICAM-1) and P-glycoprotein (P-gp). At a metabolic level, the treatment of the endothelial cells with RRMS sera reduced their glycolytic activity (measured through the extracellular acidification rate-ECAR) and oxygen consumption rate (oxidative phosphorylation rate-OCR). Such changes were associated with the down-modulation of endothelial glucose transporter 1 (GLUT-1) expression and by altered mitochondrial membrane potential. Higher level of reactive oxygen species released from the endothelial cells treated with RRMS sera indicate a pro-inflammatory status of the cells together with the higher expression of ICAM-1, endothelial cell cytoskeleton perturbation (stress fibres) as well as disruption of the cytoskeleton signal transduction MSK1/2 and β-catenin phosphorylation. Our data suggest that circulating factors present in RRMS patient serum induce physiological and biochemical alterations to the BBB, namely reducing expression of essential tightness regulators, as well as reduced engagement of glycolysis and alteration of mitochondrial potential. As these last changes have been linked with alterations in nutrient usage and metabolic function in immune cells; we propose that the BBB endothelium of MS patients may similarly undergo metabolic dysregulation, leading to enhanced permeability and increased disease susceptibility.